دورية أكاديمية
أعرض في EDS

Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?

التفاصيل البيبلوغرافية
العنوان: Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?
المؤلفون: Boonzaier NR; Cambridge Brain Tumour Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.; Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0QQ, UK., Piccirillo SG; Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK., Watts C; Cambridge Brain Tumour Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK., Price SJ; Cambridge Brain Tumour Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.; Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0QQ, UK.
المصدر: CNS oncology [CNS Oncol] 2015; Vol. 4 (6), pp. 399-410. Date of Electronic Publication: 2015 Oct 26.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Future Medicine Country of Publication: England NLM ID: 101594668 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-0915 (Electronic) Linking ISSN: 20450907 NLM ISO Abbreviation: CNS Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Future Medicine, 2012-
مواضيع طبية MeSH: Brain Neoplasms/*pathology , Glioblastoma/*pathology , Multimodal Imaging/*methods, Animals ; Brain Neoplasms/therapy ; Glioblastoma/therapy ; Humans
مستخلص: Glioblastoma demonstrates imaging features of intratumor heterogeneity that result from underlying heterogeneous biological properties. This stems from variations in cellular behavior that result from genetic mutations that either drive, or are driven by, heterogeneous microenvironment conditions. Among all imaging methods available, only T1-weighted contrast-enhancing and T2-weighted fluid-attenuated inversion recovery are used in standard clinical glioblastoma assessment and monitoring. Advanced imaging modalities are still considered emerging techniques as appropriate end points and robust methodologies are missing from clinical trials. Discovering how these images specifically relate to the underlying tumor biology may aid in improving quality of clinical trials and understanding the factors involved in regional responses to treatment, including variable drug uptake and effect of radiotherapy. Upon validation and standardization of emerging MR techniques, providing information based on the underlying tumor biology, these images may allow for clinical decision-making that is tailored to an individual's response to treatment.
References: AJNR Am J Neuroradiol. 2014 Jul;35(7):1309-17. (PMID: 24676005)
Acta Neurochir (Wien). 2012 Aug;154(8):1361-70; discussion 1370. (PMID: 22729482)
Cancer Cell. 2012 Mar 20;21(3):283-96. (PMID: 22439924)
Exp Cell Res. 2013 Dec 10;319(20):3094-103. (PMID: 23973668)
Magn Reson Med. 2010 Sep;64(3):907-13. (PMID: 20806381)
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5213-8. (PMID: 18362333)
Neuro Oncol. 2014 Oct;16 Suppl 7:vii2-11. (PMID: 25313235)
J Neurosurg. 2010 Aug;113(2):358-68. (PMID: 19895196)
Eur Radiol. 2004 Oct;14(10):1909-17. (PMID: 15221264)
ScientificWorldJournal. 2013 Apr 04;2013:796029. (PMID: 23690748)
Neuroradiology. 2006 Sep;48(9):622-31. (PMID: 16752135)
AJNR Am J Neuroradiol. 2011 May;32(5):882-9. (PMID: 21330401)
J Magn Reson Imaging. 1999 Jan;9(1):53-60. (PMID: 10030650)
J Neurooncol. 2008 May;88(1):27-35. (PMID: 18217207)
Clin Radiol. 2003 Jun;58(6):455-62. (PMID: 12788314)
J Nucl Med. 2005 Dec;46(12):1948-58. (PMID: 16330557)
Br J Radiol. 2006 Feb;79(938):101-9. (PMID: 16489190)
J Neuroradiol. 2009 May;36(2):88-92. (PMID: 19054561)
AJR Am J Roentgenol. 1998 Dec;171(6):1479-86. (PMID: 9843274)
Br J Neurosurg. 2009 Feb;23(1):5-13. (PMID: 19234903)
J Magn Reson Imaging. 1999 Sep;10(3):223-32. (PMID: 10508281)
J Neurosurg. 2007 Apr;106(4):660-6. (PMID: 17432719)
Nature. 2013 Sep 19;501(7467):346-54. (PMID: 24048067)
AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8. (PMID: 19056837)
Neuro Oncol. 2012 Jul;14(7):942-54. (PMID: 22711606)
J Magn Reson Imaging. 2008 Apr;27(4):718-25. (PMID: 18383265)
Magn Reson Med. 2005 Jun;53(6):1432-40. (PMID: 15906300)
Radiology. 2007 Aug;244(2):557-65. (PMID: 17581887)
Radiologe. 1986 Apr;26(4):206-9. (PMID: 3012629)
J Neurooncol. 2000 Dec;50(3):215-26. (PMID: 11263501)
J Clin Oncol. 2008 Jul 10;26(20):3387-94. (PMID: 18541899)
Radiology. 2013 Oct;269(1):8-15. (PMID: 24062559)
Lancet Oncol. 2006 May;7(5):392-401. (PMID: 16648043)
Science. 2014 Jun 20;344(6190):1396-401. (PMID: 24925914)
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1455-60. (PMID: 15956515)
Clin Cancer Res. 2000 Jun;6(6):2189-200. (PMID: 10873068)
Radiother Oncol. 1984 Dec;2(4):317-23. (PMID: 6395213)
J Nucl Med. 2011 Mar;52(3):424-30. (PMID: 21321268)
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14. (PMID: 23412337)
PLoS One. 2010 Mar 22;5(3):e9808. (PMID: 20339555)
AJR Am J Roentgenol. 2009 Dec;193(6):W515-22. (PMID: 19933626)
J Clin Oncol. 2010 Apr 10;28(11):1963-72. (PMID: 20231676)
Magn Reson Med. 2009 Aug;62(2):488-99. (PMID: 19466747)
Nature. 2013 Sep 19;501(7467):338-45. (PMID: 24048066)
Clin Radiol. 2009 Jan;64(1):52-63. (PMID: 19070698)
AJNR Am J Neuroradiol. 2012 Jun;33(6):1059-64. (PMID: 22268080)
Oncol Rep. 2009 Sep;22(3):641-8. (PMID: 19639216)
Sci Transl Med. 2012 Mar 28;4(127):127ps10. (PMID: 22461637)
Neoplasia. 1999 Aug;1(3):197-207. (PMID: 10935474)
Stem Cell Reports. 2015 Jan 13;4(1):7-15. (PMID: 25533637)
J Magn Reson Imaging. 2012 Nov;36(5):1072-82. (PMID: 22745032)
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36. (PMID: 11121466)
Annu Rev Biomed Eng. 1999;1:241-63. (PMID: 11701489)
Clin Neurol Neurosurg. 2010 Nov;112(9):758-65. (PMID: 20619531)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Neuro Oncol. 2001 Jul;3(3):193-200. (PMID: 11465400)
AJNR Am J Neuroradiol. 2007 Sep;28(8):1455-61. (PMID: 17846190)
J Neurooncol. 2011 Jul;103(3):575-84. (PMID: 20927570)
AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98. (PMID: 14625221)
J Nucl Med. 2005 Jun;46(6):945-52. (PMID: 15937304)
Br J Cancer. 2013 Feb 19;108(3):479-85. (PMID: 23299535)
Br J Cancer. 2012 Jul 24;107(3):462-8. (PMID: 22722315)
Neurosurgery. 2001 Oct;49(4):823-9. (PMID: 11564242)
Am J Clin Oncol. 1998 Aug;21(4):355-61. (PMID: 9708633)
J Cell Biochem. 2007 Jul 1;101(4):937-49. (PMID: 17171643)
Neoplasia. 2006 Apr;8(4):259-67. (PMID: 16756718)
J Neurooncol. 2007 May;82(3):305-11. (PMID: 17120157)
Radiat Oncol. 2014 Jun 06;9:130. (PMID: 24906388)
Cancer Res. 2015 Jan 1;75(1):194-202. (PMID: 25406193)
AJNR Am J Neuroradiol. 2011 Mar;32(3):501-6. (PMID: 21163880)
J Neurooncol. 2012 Jul;108(3):491-8. (PMID: 22426926)
Lancet Oncol. 2008 May;9(5):453-61. (PMID: 18452856)
AJNR Am J Neuroradiol. 2006 Oct;27(9):1969-74. (PMID: 17032877)
Radiology. 2010 Mar;254(3):876-81. (PMID: 20089718)
Eur Radiol. 2007 Jul;17(7):1675-84. (PMID: 17219140)
Medicina (Kaunas). 2012;48(10):497-506. (PMID: 23324245)
معلومات مُعتمدة: NIHR/CS/009/011 United Kingdom DH_ Department of Health; United Kingdom CRUK_ Cancer Research UK
فهرسة مساهمة: Keywords: advanced imaging; glioblastoma; intratumor heterogeneity; subregional assessment; underlying biology
تواريخ الأحداث: Date Created: 20151027 Date Completed: 20160823 Latest Revision: 20220129
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6083939
DOI: 10.2217/cns.15.20
PMID: 26497327
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-0915
DOI:10.2217/cns.15.20